Property Summary

NCBI Gene PubMed Count 22
PubMed Score 33.50
PubTator Score 32.65

Knowledge Summary


No data available


  Disease (3)


  Differential Expression (3)

Disease log2 FC p
osteosarcoma 1.178 2.0e-05
pancreatic cancer 1.200 7.0e-05
pituitary cancer -1.600 1.2e-07


Accession Q96JT2 A8K2U9
Symbols PRST


PANTHER Protein Class (2)

  Ortholog (1)

Species Source Disease
Chimp OMA EggNOG

Gene RIF (14)

26938874 CTCF has a role in regulating SLC45A3-ELK4 Chimeric RNA
25434496 genome-wide association studies show that the top SNP associated with log PSA 9Prostate-specific antigen) levels was rs2153904 in SLC45A3.
23269536 Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
22821757 This study provides first evidence that the expression of SLC45A3 protein is down regulated through SLC45A3-ERG fusion in prostate cancer.
22719019 Data suggest that chimeric SLC45A3-ELK4 controls prostate cancer cell proliferation, and the chimera level correlates with prostate cancer disease progression.
21777423 Double sequential immunohistochemical staining with p63 and P501S is highly specific and can be a useful tool in distinguishing urothelial carcinoma from prostate carcinoma.
20118910 This is the first study to report concurrent TMPRSS2 and SLC45A3 rearrangements in the same tumor focus in prostate cancer
19649210 This study demonstrates that most ERG-overexpressing prostate cancers harbor hormonally regulated TMPRSS2-ERG, SLC45A3-ERG, or NDRG1-ERG fusions
19136943 SLC45A3-ELK4 may represent the first description of a recurrent RNA chimaeric transcript specific to prostate cancer that does not have a detectable DNA aberration
18193184 Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype.
18172298 A SLC45A3:ETV5 gene fusion was identified in prostate cancer.
17721190 P501S is a sensitive and highly specific marker for identifying prostate tissue. Combined use of prostein/prostate specific antigen used to detect prostatic origin of metastatic carcinomas.
15176054 Prostein is expressed in the vast majority of prostatic tissues, regardless of grade and metastatic status. No expression was detected in 4,700 normal and malignant tissue samples representing the great majority of essential tissues and tumors.
15048720 T cells that recognize naturally processed epitopes from prostein were expanded from healthy donors and characterized. T cells isolated from males were of low avidity and recognized subdominant epitopes while those from females were of higher avidity

AA Sequence


Text Mined References (23)

PMID Year Title
26938874 2016 Role of CTCF in Regulating SLC45A3-ELK4 Chimeric RNA.
25434496 2015 Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate-specific antigen for prostate cancer screening in two Korean population-based cohort studies.
24919509 2014 A genome-wide association study of serum levels of prostate-specific antigen in the Japanese population.
23269536 2013 Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
22821757 2013 Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
22719019 2012 Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation.
21777423 2011 Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma.
21738478 2011 Identification of nine novel loci associated with white blood cell subtypes in a Japanese population.
20118910 2010 Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
19915576 2009 Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.
19649210 2009 N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
19136943 2009 Transcriptome sequencing to detect gene fusions in cancer.
18193184 2008 Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells.
18172298 2008 Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
17721190 2007 The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
16344560 2006 Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.
15489334 2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
15176054 2004 Prostein expression is highly restricted to normal and malignant prostate tissues.
15048720 2004 Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate.
14997204 2004 Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.
14702039 2004 Complete sequencing and characterization of 21,243 full-length human cDNAs.
12477932 2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.
11245466 2001 Identification and characterization of prostein, a novel prostate-specific protein.